Filter posts

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

The Rise of Specialty Pharmaceuticals

Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, …